Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (1487)	2/10/2002 6:50:42 PM
From: tnsaf	Read Replies (1) \| Respond to of 7143

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis Proc. Natl. Acad. Sci. USA, Vol. 99, Issue 3, 1521-1526, February 5, 2002 Reade B. Roberts, Lu Min, M. Kay Washington§,¶, Sandra J. Olsen§, Stephen H. Settle, Robert J. Coffey,¶,~, and David W. Threadgill,¶,~ Departments of * Cell Biology, § Pathology, and ~ Medicine, and ¶ Vanderbilt-Ingram Cancer Center, Vanderbilt University and Veterans Affairs Medical Center, 1161 21st Avenue South, Nashville, TN 37232 We used the hypomorphic Egfrwa2 allele to genetically examine the impact of impaired epidermal growth factor receptor (Egfr) signaling on the ApcMin mouse model of familial adenomatous polyposis. Transfer of the ApcMin allele onto a homozygous Egfrwa2 background results in a 90% reduction in intestinal polyp number relative to ApcMin mice carrying a wild-type Egfr allele. This Egfr effect is potentially synergistic with the actions of the modifier-of-min (Mom1) locus. Surprisingly, the size, expansion, and pathological progression of the polyps appear Egfr-independent. Histological examination of the ilea of younger animals revealed no differences in the number of microadenomas, the presumptive precursor lesions to gross intestinal polyps. Pharmacological inhibition with EKI-785, an Egfr tyrosine kinase inhibitor, produced similar results in the ApcMin model. These data suggest that normal Egfr activity is required for establishment of intestinal tumors in the ApcMin model between initiation and subsequent expansion of initiated tumors. The role of Egfr signaling during later stages of tumorigenesis was examined by using nude mice xenografts of two human colorectal cancer cell lines. Treatment with EKI-785 produced a dose-dependent reduction in tumor growth, suggesting that Egfr inhibitors may be useful for advanced colorectal cancer treatment. ------------------------------------------------------------ www.pnas.org/cgi/doi/10.1073/pnas.032678499